Duke University Medical Center, 10 Bryan Searle Drive, 477 Seeley G. Mudd Building, Durham, NC 27710, USA.
Cancer vaccines have demonstrated clinical benefit, however greater efficacy could be achieved by enhancing their immunogenicity. Owing to cancer vaccines depending on uptake and cross-presentation of tumor antigens by antigen-presenting cells (APCs), we hypothesized that greater immunogenicity would accompany strategies that direct antigen to APC-expressed mannose receptors, initiating a pathway increasing class I and II presentation to T cells. CDX-1307 consists of a human monoclonal antibody targeting the mannose receptor, fused to the human chorionic gonadotropin-β chain (hCG-β), a tumor antigen frequently expressed by epithelial cancers including bladder cancer. In Phase I studies of cancer patients, CDX-1307 was well tolerated and induced significant hCG-β-specific cellular and humoral immune responses when co-administered with GM-CSF and the Toll-like receptor agonists resiquimod and poly-ICLC. An ongoing Phase II trial evaluates CDX-1307 in patients with newly diagnosed, resectable, hCG-β-expressing bladder cancer, where low tumor burden and early intervention may provide greater potential for benefit.
Written by:
Morse MA, Bradley DA, Keler T, Laliberte RJ, Green JA, Davis TA, Inman BA. Are you the author?
Reference: Expert Rev Vaccines. 2011 Jun;10(6):733-42.
doi: 10.1586/erv.11.20
PubMed Abstract
PMID: 21692696
UroToday.com Bladder Cancer Section
